Pharmacology of Antiarrhythmic Drugs

Introduction/Overview

Antiarrhythmic drugs constitute a critical therapeutic class designed to suppress or prevent abnormal cardiac rhythms, known as arrhythmias. These disorders of cardiac impulse formation or conduction can range from benign palpitations to life-threatening ventricular tachyarrhythmias, contributing significantly to global cardiovascular morbidity and mortality. The fundamental goal of antiarrhythmic pharmacotherapy is to restore and maintain normal sinus rhythm, control ventricular rate, and reduce the risk of thromboembolic complications, thereby improving cardiac output and preventing sudden cardiac death. The clinical use of these agents requires a precise understanding of cardiac electrophysiology, as the drugs themselves possess a narrow therapeutic index and a well-documented potential to exacerbate arrhythmias, a phenomenon termed proarrhythmia.

The clinical relevance of these agents remains paramount despite advances in non-pharmacological interventions like catheter ablation and implantable cardioverter-defibrillators (ICDs). Pharmacological management is often essential for acute rhythm control, as an adjunct to devices, or for long-term therapy in patients where invasive procedures are contraindicated or unavailable. The complexity of antiarrhythmic pharmacology stems from the diverse molecular targets involved in cardiac action potentials and the profound influence of underlying cardiac pathology, autonomic tone, and electrolyte balance on drug efficacy and safety.

Learning Objectives

• Classify antiarrhythmic drugs according to the Vaughan Williams system and the Sicilian Gambit framework, explaining the mechanistic basis for each category.
• Describe the detailed pharmacodynamic actions of each major drug class on cardiac ion channels, receptors, and action potential morphology in different myocardial tissues.
• Analyze the pharmacokinetic profiles of key antiarrhythmic agents, including absorption, distribution, metabolism, excretion, and implications for dosing in special populations.
• Evaluate the approved clinical indications, major adverse effects, and proarrhythmic risks associated with each class of antiarrhythmic drug.
• Integrate knowledge of drug interactions and special considerations (e.g., renal/hepatic impairment, pregnancy) to formulate appropriate therapeutic plans for patients with arrhythmias.

Classification

The most widely adopted organizational scheme for antiarrhythmic drugs is the Vaughan Williams classification, which categorizes agents based on their primary electrophysiological mechanism of action. It is important to recognize that this system has limitations, as many drugs exhibit actions across multiple classes, and their clinical effects are influenced by factors such as tissue type, heart rate, and membrane potential. An alternative, more detailed conceptual approach is provided by the Sicilian Gambit, which emphasizes the drug’s effects on specific channels, receptors, and pumps within the context of arrhythmia mechanisms.

Vaughan Williams Classification

• Class I: Sodium Channel Blockers. These drugs inhibit the fast inward sodium current (I_Na), slowing phase 0 depolarization in atrial, ventricular, and Purkinje fibers. They are subdivided based on their kinetics of association and dissociation with the sodium channel.
  • Class IA: Moderate sodium channel blockade with intermediate dissociation kinetics. Examples: quinidine, procainamide, disopyramide.
  • Class IB: Fast dissociation kinetics, exhibiting preferential blockade of inactivated or open sodium channels. Examples: lidocaine, mexiletine.
  • Class IC: Potent sodium channel blockade with slow dissociation kinetics, causing marked slowing of conduction. Examples: flecainide, propafenone.
• Class II: Beta-Adrenergic Receptor Antagonists. These drugs competitively inhibit sympathetic nervous system effects on the heart, primarily by blocking β₁-adrenoceptors. Their antiarrhythmic effects are mediated through reducing pacemaker automaticity (phase 4 depolarization) and slowing atrioventricular (AV) nodal conduction. Examples: propranolol, metoprolol, esmolol, atenolol.
• Class III: Potassium Channel Blockers. This class primarily blocks the rapid component of the delayed rectifier potassium current (I_Kr), prolonging the action potential duration (APD) and effective refractory period (ERP). Examples: amiodarone, sotalol, dofetilide, ibutilide.
• Class IV: Calcium Channel Blockers. These agents block L-type calcium channels, depressing phase 2 (plateau) and phase 4 depolarization in sinoatrial (SA) and AV nodal cells. Examples: verapamil, diltiazem.
• Unclassified Agents: Several important antiarrhythmic drugs do not fit neatly into the above classes. These include adenosine, digoxin, magnesium sulfate, and ivabradine, each with distinct mechanisms.

Chemical Classification

While the Vaughan Williams system is functionally based, chemical structure influences pharmacokinetics and receptor affinity. Class I drugs are often local anesthetic analogues or derivatives. Class III agents are structurally diverse, ranging from iodinated benzofuran derivatives (amiodarone) to methanesulfonamilides (dofetilide, ibutilide). Beta-blockers share an aryloxypropanolamine structure, while calcium channel blockers are heterogeneous, with verapamil being a phenylalkylamine and diltiazem a benzothiazepine.

Mechanism of Action

The antiarrhythmic effect of these drugs is achieved by modulating the electrophysiological properties of cardiac myocytes. The cardiac action potential is generated by the sequential opening and closing of specific ion channels. By altering the flux of sodium, potassium, calcium, or chloride ions, these drugs change the action potential’s shape, duration, and propagation, thereby suppressing abnormal automaticity, blocking re-entrant circuits, or modifying triggered activity.

Class I: Sodium Channel Blockers

Class I drugs bind to specific sites on the voltage-gated sodium channel, stabilizing it in its inactivated state. This use-dependent or state-dependent blockade is more pronounced at faster heart rates (when channels cycle more frequently) and in depolarized tissues (e.g., ischemic myocardium). The degree of conduction slowing correlates with the extent of sodium channel blockade.

Class IA agents exhibit moderate sodium channel blockade and also prolong repolarization by blocking potassium channels (primarily I_Kr), imparting Class III activity. This results in slowed conduction (increased QRS duration) and prolonged repolarization (increased QT interval). Class IB drugs have rapid binding/unbinding kinetics, producing minimal effects on normal Purkinje and ventricular tissue at normal heart rates but significant blockade in ischemic or depolarized tissues. They may shorten repolarization in some tissues by altering potassium currents. Class IC drugs cause profound slowing of conduction throughout the His-Purkinje system and myocardium with minimal effect on repolarization, leading to significant QRS widening without substantial QT prolongation.

Class II: Beta-Adrenergic Receptor Antagonists

Beta-blockers exert antiarrhythmic effects primarily by antagonizing catecholamine binding at cardiac β₁-adrenoceptors. This reduces cyclic adenosine monophosphate (cAMP) production, which in turn decreases the activity of pacemaker currents (I_f in SA node) and calcium currents (I_Ca,L). The consequences include a reduction in sinus node automaticity (decreased heart rate), slowed conduction through the AV node (increased PR interval), and inhibition of triggered activity caused by delayed afterdepolarizations (DADs). They also raise the ventricular fibrillation threshold and have beneficial effects in myocardial ischemia by reducing oxygen demand.

Class III: Potassium Channel Blockers

The principal action of Class III drugs is blockade of the rapid delayed rectifier potassium current (I_Kr), which is responsible for phase 3 repolarization. By delaying potassium efflux, these drugs prolong the action potential duration (APD) and the effective refractory period (ERP) in atrial, ventricular, and Purkinje tissues. This can terminate re-entrant arrhythmias by converting tissue ahead of the circulating wavefront from excitable to refractory. Some agents, like amiodarone and dronedarone, have multichannel blocking properties, affecting sodium, calcium, and beta-adrenergic receptors as well. Sotalol is a racemic mixture where the d-isomer has pure Class III activity and the l-isomer has additional beta-blocking properties.

Class IV: Calcium Channel Blockers

Non-dihydropyridine calcium channel blockers, verapamil and diltiazem, selectively inhibit L-type calcium channels in cardiac nodal tissue (SA and AV nodes) and, to a lesser extent, in myocardial cells. By reducing the slow inward calcium current (I_Ca,L) during phase 2 and phase 4, they depress depolarization in nodal cells. This results in decreased automaticity of the SA node, slowed conduction through the AV node (increased PR interval), and a prolonged refractory period of the AV node. Their effects are most pronounced in tissues dependent on calcium currents for depolarization.

Unclassified Agents

Adenosine activates inward rectifying potassium channels (I_K(Ado)) via A₁ receptors, hyperpolarizing the SA and AV nodes and inhibiting cAMP-stimulated calcium current. This produces transient sinus bradycardia and profound AV nodal blockade. Digoxin inhibits the Na+/K+ ATPase pump, increasing intracellular sodium, which indirectly reduces calcium extrusion via the Na+/Ca²⁺ exchanger, leading to positive inotropy. Its vagotonic effects slow AV nodal conduction. Magnesium sulfate may act as a natural calcium channel antagonist and stabilize myocardial cell membranes. Ivabradine selectively inhibits the I_f (“funny”) current in the SA node, reducing heart rate without affecting contractility or AV conduction.

Pharmacokinetics

The pharmacokinetic properties of antiarrhythmic drugs are highly variable and critically important for dosing, monitoring, and predicting drug interactions. Many exhibit complex metabolism and have active metabolites that contribute to their therapeutic and toxic effects.

Absorption and Distribution

Most antiarrhythmic drugs are well absorbed orally, with bioavailability ranging from high (e.g., flecainide >90%) to moderate and variable due to significant first-pass metabolism (e.g., propranolol, verapamil, lidocaine). Amiodarone is poorly and variably absorbed (35-65%). Distribution is generally extensive, with large volumes of distribution (V_d), often exceeding total body water. Many are highly protein-bound, primarily to alpha-1 acid glycoprotein, an acute phase reactant whose levels can increase during illness, potentially altering free drug concentration. Amiodarone is exceptionally lipophilic, leading to extensive sequestration in adipose tissue and a very large V_d (≈60 L/kg).

Metabolism and Excretion

Metabolic pathways are diverse. Several agents are metabolized by the hepatic cytochrome P450 system, creating potential for numerous drug interactions.

• CYP2D6: Propafenone, flecainide, metoprolol. Genetic polymorphism in CYP2D6 activity can lead to poor or extensive metabolizer phenotypes, significantly affecting drug levels and response.
• CYP3A4: This is a major pathway for quinidine, disopyramide, lidocaine, verapamil, diltiazem, and amiodarone. Inhibitors (e.g., macrolides, azole antifungals) and inducers (e.g., rifampin, phenytoin) of CYP3A4 can dramatically alter concentrations.
• Other Pathways: Procainamide is acetylated by N-acetyltransferase (NAT2) to form N-acetylprocainamide (NAPA), an active metabolite with Class III properties. Acetylation rate is genetically determined.

Renal excretion of unchanged drug is significant for several agents, including digoxin (mostly unchanged), sotalol (>90% unchanged), dofetilide (80% unchanged), and the NAPA metabolite of procainamide. Dosage adjustment is mandatory in renal impairment for these drugs. Hepatic impairment necessitates caution with drugs like lidocaine, amiodarone, and verapamil.

Half-life and Dosing Considerations

Elimination half-lives (t_1/2) vary widely, influencing dosing frequency and time to steady-state.

• Short t_1/2 (minutes to a few hours): Adenosine (seconds), esmolol (9 min), lidocaine (1-2 h), procainamide (3-5 h). These often require intravenous infusion or frequent oral dosing.
• Intermediate t_1/2 (6-12 hours): Mexiletine, flecainide, propafenone, immediate-release metoprolol.
• Long t_1/2 ( >24 hours): Amiodarone has an exceptionally long and variable t_1/2 of 25-110 days due to extensive tissue storage, necessitating complex loading regimens. Digoxin (36-48 h), sustained-release formulations of many drugs.

The concept of therapeutic drug monitoring (TDM) is applied to certain antiarrhythmics (e.g., digoxin, procainamide/NAPA, quinidine) to maintain plasma concentrations within a narrow therapeutic window and avoid toxicity.

Therapeutic Uses/Clinical Applications

The selection of an antiarrhythmic drug is guided by the type of arrhythmia (supraventricular vs. ventricular), the presence of structural heart disease, left ventricular function, and comorbid conditions. The principle of “choosing the right drug for the right patient” is paramount to maximize benefit and minimize proarrhythmic risk.

Supraventricular Arrhythmias

Atrial Fibrillation (AF) and Atrial Flutter: Goals include rate control, rhythm control, and prevention of thromboembolism. For rate control, beta-blockers, non-dihydropyridine calcium channel blockers (verapamil, diltiazem), and digoxin are first-line. For rhythm control (cardioversion and maintenance of sinus rhythm), drug choice depends on cardiac structure.

• No or minimal heart disease: Flecainide, propafenone (often with an AV nodal blocker), or sotalol.
• Coronary artery disease: Sotalol or dofetilide.
• Heart failure with reduced ejection fraction (HFrEF): Amiodarone or dofetilide.
• Hypertensive heart disease (without LVH): Similar to no heart disease; with significant LVH, amiodarone is preferred due to the proarrhythmic risk of Class I drugs.

Paroxysmal Supraventricular Tachycardias (PSVT): AV nodal re-entrant tachycardia (AVNRT) and AV re-entrant tachycardia (AVRT) are often acutely terminated by adenosine, verapamil, or beta-blockers. For long-term prophylaxis, beta-blockers, verapamil/diltiazem, or Class IC drugs (in absence of structural disease) may be used.

Ventricular Arrhythmias

Ventricular Tachycardia (VT) and Ventricular Fibrillation (VF): Acute management of sustained VT often involves intravenous amiodarone, lidocaine, or procainamide. For long-term suppression of life-threatening ventricular arrhythmias and prevention of sudden cardiac death, especially in patients with ICDs experiencing frequent shocks, oral amiodarone, mexiletine (often combined with amiodarone), or sotalol are employed. Beta-blockers are cornerstone therapy for ventricular arrhythmias in the context of long QT syndrome, catecholaminergic polymorphic VT, and post-myocardial infarction.

Premature Ventricular Complexes (PVCs): Treatment is usually reserved for symptomatic patients. Beta-blockers are first-line. Class I agents (e.g., flecainide) may be considered in patients without structural heart disease.

Other Specific Indications

• Digoxin: Rate control in AF, especially in patients with heart failure.
• Magnesium Sulfate: First-line for torsades de pointes associated with long QT interval; also used in digoxin toxicity.
• Ivabradine: For heart rate reduction in chronic heart failure (NYHA class II-III) with sinus rhythm and elevated heart rate, and in stable coronary artery disease.

Adverse Effects

Adverse effects of antiarrhythmic drugs are common and can be organ-specific or related to their electrophysiological actions. The risk of proarrhythmia is a class-wide concern.

Common Side Effects

Side effects often correlate with the drug’s primary pharmacological action.

• Class I: Gastrointestinal disturbances (quinidine diarrhea, procainamide nausea), neurological effects (lidocaine dizziness, paresthesias; flecainide visual blurring), negative inotropy (disopyramide).
• Class II: Bradycardia, fatigue, bronchospasm (in asthma/COPD), erectile dysfunction, masking of hypoglycemia symptoms.
• Class III: Amiodarone: photosensitivity, corneal microdeposits, thyroid dysfunction (hypo- or hyperthyroidism), pulmonary fibrosis, hepatotoxicity, peripheral neuropathy. Sotalol: fatigue, bradycardia (from beta-blockade). Dofetilide: headache, dizziness.
• Class IV: Constipation (verapamil), peripheral edema, bradycardia, headache, negative inotropy.

Serious Adverse Reactions and Proarrhythmia

The most feared complication is the provocation of new or worsened arrhythmias.

• Torsades de Pointes: A polymorphic VT associated with QT interval prolongation. It is a significant risk with Class IA (quinidine, procainamide) and Class III drugs (sotalol, dofetilide, ibutilide). Amiodarone, despite prolonging QT, carries a lower risk due to its homogeneous prolongation of APD and multichannel effects.
• Ventricular Proarrhythmia (Class IC effect): Flecainide and propafenone can cause a potentially fatal, incessant monomorphic VT, particularly in patients with structural heart disease (e.g., post-MI) or atrial flutter with 1:1 AV conduction.
• Organ Toxicity: Amiodarone’s long-term use is limited by cumulative toxicities: pulmonary fibrosis (potentially fatal), hepatotoxicity, and thyrotoxicosis or hypothyroidism. Procainamide can cause a drug-induced lupus erythematosus syndrome. Quinidine can cause cinchonism (tinnitus, hearing loss) and immune thrombocytopenia.

Black Box Warnings

Several antiarrhythmic drugs carry FDA-mandated black box warnings, the strongest safety alert.

• Dofetilide: Must be initiated in a hospital setting with continuous ECG monitoring for at least 3 days due to risk of torsades de pointes. Dose must be adjusted based on creatinine clearance and QTc interval.
• Flecainide and Propafenone: Contraindicated in patients with structural heart disease (e.g., prior MI, cardiomyopathy) due to increased mortality from proarrhythmia and cardiac arrest, as demonstrated in the Cardiac Arrhythmia Suppression Trial (CAST).
• Amiodarone: Warns of potentially fatal pulmonary toxicity, hepatotoxicity, and exacerbation of arrhythmias.
• Sotalol: Risk of life-threatening ventricular tachycardia associated with QT prolongation. Initiation and dose increases should be done in a monitored setting.

Drug Interactions

Antiarrhythmic drugs are involved in numerous pharmacokinetic and pharmacodynamic interactions, often increasing the risk of toxicity or reducing efficacy.

Major Pharmacokinetic Interactions

• Enzyme Inhibition: Amiodarone is a potent inhibitor of CYP3A4, CYP2C9, and P-glycoprotein. It can dramatically increase levels of digoxin, warfarin (increased INR), simvastatin (increased myopathy risk), and many others. Quinidine inhibits CYP2D6 and P-glycoprotein.
• Enzyme Induction: Drugs like phenytoin, rifampin, and carbamazepine can induce CYP3A4, reducing plasma concentrations of verapamil, diltiazem, disopyramide, and potentially amiodarone.
• Competition for Renal Secretion: Drugs that inhibit renal tubular secretion (e.g., cimetidine, trimethoprim) can increase plasma levels of dofetilide and sotalol.

Major Pharmacodynamic Interactions

• Additive Bradycardia/Conduction Delay: Concomitant use of beta-blockers, calcium channel blockers, and digoxin can cause profound bradycardia or heart block.
• Additive Negative Inotropy: Combining disopyramide, flecainide, or beta-blockers with verapamil can precipitate heart failure.
• Additive QT Prolongation: Combining Class IA or III drugs with other QT-prolonging agents (e.g., macrolide antibiotics, antipsychotics, tricyclic antidepressants, certain antifungals) synergistically increases the risk of torsades de pointes.
• Electrolyte Disturbances: Diuretic-induced hypokalemia and hypomagnesemia potentiate the proarrhythmic effects of many antiarrhythmics, particularly those that prolong the QT interval.

Contraindications

Absolute contraindications are specific to each drug but commonly include:

• Severe bradycardia, sick sinus syndrome, or high-grade AV block (for most agents affecting nodal conduction).
• Cardiogenic shock, severe hypotension.
• Asthma/COPD (for non-cardioselective beta-blockers).
• Structural heart disease, particularly coronary artery disease with prior MI or reduced LVEF (for Class IC drugs).
• Congenital or acquired long QT syndrome (for most QT-prolonging drugs).
• Severe renal impairment (for drugs renally excreted like dofetilide, sotalol).

Special Considerations

Pregnancy and Lactation

Most antiarrhythmic drugs cross the placenta and are excreted in breast milk. Treatment decisions must balance maternal benefit against fetal/neonatal risk.

• Generally Considered Safer Options: Beta-blockers (particularly metoprolol, labetalol), digoxin, and verapamil are often used when necessary. Adenosine is safe for acute termination of SVT.
• Use with Caution/Contraindicated: Amiodarone is generally avoided due to risks of fetal hypothyroidism, goiter, and potential teratogenicity. Class IA and IC drugs may be used in refractory, life-threatening maternal arrhythmias. Dofetilide and sotalol are typically avoided due to limited data.
• Lactation: Many drugs are present in milk. Amiodarone, with its long half-life and iodine content, is contraindicated. Beta-blockers like propranolol and metoprolol are considered compatible, though the infant should be monitored for bradycardia.

Pediatric and Geriatric Considerations

Pediatrics: Dosing is typically weight-based (mg/kg). Pharmacokinetics can differ due to variations in body composition, protein binding, and organ maturation. Digoxin, beta-blockers (e.g., propranolol), and amiodarone are used for specific pediatric arrhythmias. Close monitoring is essential.

Geriatrics: Age-related changes significantly impact therapy: reduced renal and hepatic clearance, decreased lean body mass and total body water (altering V_d), increased fat proportion (affecting distribution of lipophilic drugs), and polypharmacy increasing interaction risk. A “start low, go slow” approach is warranted. Dose reduction is frequently required for renally excreted drugs (digoxin, sotalol). Increased sensitivity to CNS side effects (e.g., from lidocaine) and orthostatic hypotension is common.

Renal and Hepatic Impairment

Renal Impairment: Dosage adjustment is critical for drugs primarily excreted unchanged by the kidneys. This includes digoxin, sotalol, dofetilide, procainamide (and its metabolite NAPA), and flecainide (to a lesser extent). Dosing is typically guided by creatinine clearance (CrCl). For dofetilide, the dose is strictly determined by CrCl and QTc interval.

Hepatic Impairment: Drugs with extensive hepatic metabolism or high first-pass effect require caution. Lidocaine infusion rates must be reduced due to decreased clearance. Doses of amiodarone, quinidine, verapamil, diltiazem, and propafenone may need reduction. Monitoring for signs of toxicity is essential, as protein binding may also be altered in liver disease.

Summary/Key Points

• Antiarrhythmic drugs are classified primarily by their electrophysiological actions (Vaughan Williams: Classes I-IV), though many have multi-channel effects.
• Their mechanisms involve modulation of specific cardiac ion channels (sodium, potassium, calcium) or receptors (beta-adrenergic, adenosine), altering action potential generation and propagation to suppress arrhythmogenic foci or re-entrant circuits.
• Pharmacokinetics are highly variable; understanding metabolism (often via CYP450 enzymes) and excretion (renal vs. hepatic) is crucial for safe dosing and anticipating drug interactions.
• Clinical application is dictated by the specific arrhythmia and the presence or absence of underlying structural heart disease. Class IC agents are contraindicated in patients with coronary artery disease or cardiomyopathy.
• The most serious class-wide adverse effect is proarrhythmia, including torsades de pointes (from QT prolongation) and ventricular tachycardia facilitation (especially with Class IC drugs).
• Numerous and potentially severe drug interactions occur, both pharmacokinetic (CYP450 inhibition/induction) and pharmacodynamic (additive bradycardia, QT prolongation, negative inotropy).
• Special populations require tailored therapy: dose adjustment in renal/hepatic impairment, cautious selection in pregnancy/lactation, and careful titration in geriatric patients.

Clinical Pearls

• Always assess for structural heart disease before initiating a Class I antiarrhythmic, especially flecainide or propafenone.
• Monitor the QTc interval closely when using Class IA or III drugs; correct hypokalemia and hypomagnesemia aggressively.
• Consider amiodarone’s exceptionally long half-life and multi-organ toxicity profile when prescribing; baseline and periodic monitoring of pulmonary, hepatic, and thyroid function is mandatory.
• In atrial flutter, always co-administer an AV nodal blocking agent (beta-blocker, calcium channel blocker) with a Class IC drug to prevent 1:1 AV conduction and rapid ventricular response.
• For drugs with a high risk of torsades de pointes (dofetilide, sotalol, ibutilide), initiation and dose titration should be performed in a monitored inpatient setting.

References

1. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
2. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.
3. Trevor AJ, Katzung BG, Kruidering-Hall M. Katzung & Trevor's Pharmacology: Examination & Board Review. 13th ed. New York: McGraw-Hill Education; 2022.
4. Golan DE, Armstrong EJ, Armstrong AW. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. 4th ed. Philadelphia: Wolters Kluwer; 2017.
5. Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 14th ed. New York: McGraw-Hill Education; 2023.
6. Katzung BG, Vanderah TW. Basic & Clinical Pharmacology. 15th ed. New York: McGraw-Hill Education; 2021.
7. Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale's Pharmacology. 9th ed. Edinburgh: Elsevier; 2020.
8. Whalen K, Finkel R, Panavelil TA. Lippincott Illustrated Reviews: Pharmacology. 7th ed. Philadelphia: Wolters Kluwer; 2019.